Michael Cola resigns from Shire
pharmafile | April 3, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Michael Cola, Shire
Michael Cola has resigned as the president of Shire Specialty Pharmaceuticals after seven years at the firm.
“On behalf of everyone at Shire, I would like to thank Mike for his devoted service to the company, and his leadership role in many important initiatives,” said Angus Russell, chief executive of Shire.
“He leaves the SP business in a great position to execute our growth strategy going forward.”
Cola joined Shire in 2005 as executive VP and general manager for the global therapeutic business units. He assumed the role of president of the SP business in 2006. Prior to joining Shire, Cola held several executive positions at Merck, AstraZeneca, and Safeguard Scientifics.
A search for a new president of Shire’s global SP business has begun. Angus Russell will assume responsibility for leading the business until a new president is appointed.
Shire said that Cola would be available to Shire through 1 June, in order to facilitate a smooth transition.
Related Content

Takeda plans to vacate all 1,000 staff from US HQ by the year’s end
Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, …

Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss …

Top Ten most popular articles on Pharmafile.com this week!
With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger …






